LINC02270: A Long Intergenic Non-Protein-Coding RNA (G101929019)

Target Name: LINC02270

NCBI ID: G101929019

LINC02270

Other Name(s): long intergenic non-protein coding RNA 2270 | Long intergenic non-protein coding RNA 2270

LINC02270: A Long Intergenic Non-Protein-Coding RNA

RNA-based therapies have emerged as a promising approach in the treatment of various diseases, including cancer. One of the promising targets for these therapies is long intergenic non-protein-coding RNAs (lncNPCRs), which have been identified as potential drug targets or biomarkers. In this article, we will explore LINC02270, a lncNPCR that has gained significant interest due to its potential as a drug target or biomarker.

LINC02270 is a transcribed RNA molecule that has been identified in various organisms, including humans. It is characterized by its ability to interact with protein-coding genes and its involvement in various cellular processes, including cell adhesion, migration, and survival. LINC02270 is a good candidate as a drug target or biomarker due to its unique structure and its potential to modulate gene expression in various pathways.

One of the key features of LINC02270 is its ability to interact with protein-coding genes. This interaction allows LINC02270 to influence the activity of these genes and potentially contribute to the development of various diseases. For example, LINC02270 has been shown to interact with the protein known as PDCD1, which is a key regulator of the blood-brain barrier. The interaction between LINC02270 and PDCD1 has been shown to promote the delivery of LINC02270 to the brain, where it can potentially contribute to the development of neurodegenerative diseases.

Another potential mechanism by which LINC02270 may contribute to the development of diseases is its involvement in cell adhesion and migration. LINC02270 has been shown to play a role in the regulation of cell-cell adhesion and has been implicated in the development of various diseases, including cancer. For example, LINC02270 has been shown to be involved in the regulation of the migration of cancer cells. This may contribute to the development of cancer stem cells, which can potentially contribute to the development of various diseases.

In addition to its potential role in cell adhesion and migration, LINC02270 has also been shown to be involved in the regulation of cellular processes that are important for the survival of cells. For example, LINC02270 has been shown to play a role in the regulation of apoptosis, which is a natural mechanism for cell death that is important for the regulation of cellular processes and the maintenance of tissue homeostasis. This may contribute to the development of various diseases, including cancer, where apoptosis may be disrupted.

In conclusion, LINC02270 is a lncNPCR that has gained significant interest due to its potential as a drug target or biomarker. Its unique structure and ability to interact with protein-coding genes make it a promising target for small molecules and other therapeutic agents. Further research is needed to fully understand the role of LINC02270 in various cellular processes and its potential as a therapeutic agent.

Protein Name: Long Intergenic Non-protein Coding RNA 2270

The "LINC02270 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02270 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets